Accelerate DiagnosticsAXDX
About: Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.
Employees: 134
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
3,300% more call options, than puts
Call options by funds: $34K | Put options by funds: $1K
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
66% more capital invested
Capital invested by funds: $5.02M [Q2] → $8.33M (+$3.31M) [Q3]
12% more funds holding
Funds holding: 41 [Q2] → 46 (+5) [Q3]
0.83% more ownership
Funds ownership: 19.48% [Q2] → 20.3% (+0.83%) [Q3]
69% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 13
Research analyst outlook
We haven’t received any recent analyst ratings for AXDX.
Financial journalist opinion
Based on 4 articles about AXDX published over the past 30 days
